Pilot Investigation of Stem Cells in Stroke (PISCES)
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||A Phase I Safety Trial of CTX0E03 Drug Product Delivered Intracranially in the Treatment of Patients With Stable Ischemic Stroke|
- Incidence of adverse events [ Time Frame: 1 year ]AEs monitored include vital signs, C-reactive protein and full blood count, structural MRI to seek evidence of hemorrhage, new infarction, inflammation or tumor, NIHSS measure (changes greater than 4) to indicate clinically significant neurological deterioration, neurological examination, CTX0E03 antibody screen, changes to concomitant medications
- Barthel Index [ Time Frame: 1 year ]Measure of functional outcome (based on activities of daily living)
- Mini-Mental State Examination [ Time Frame: 1 year ]Measure of cognitive impairment
- modified Rankin Score [ Time Frame: 1 year ]Measure of overall disability and handicap
- EQ-5D [ Time Frame: 1 year ]Measure of health-related quality of life outcomes
|Study Start Date:||June 2010|
|Estimated Study Completion Date:||March 2023|
|Primary Completion Date:||March 2015 (Final data collection date for primary outcome measure)|
Experimental: CTX0E03 DP
human neural stem cell product, once only injection, increasing doses
Biological: CTX0E03 neural stem cells
Single administration by surgical delivery to the damaged area of the brain
Design: The trial is an open label, single administration, ascending dose, single site trial using CTX neural stem cells with 24-month patient monitoring following treatment.
Pre-treatment selection of patients : Males aged ≥60 years with unilateral ischaemic stroke affecting sub-cortical white matter and/or basal ganglia 6 months to 5 years prior to entry into the study, with persistent unilateral hemiparesis, a minimum infarct diameter of 1 cm and stable neurological functional deficit as determined by the NIH Stroke Scale, (measured twice at least 1 month apart), will be eligible for treatment.
Treatment: The CTX cells will be injected by stereotaxic procedures into the putamen region of the brain of the patient under general anesthesia with imaging guidance to locate injection site. Four ascending doses of CTX cells will be tested in 12 patients (4 dosage groups of three patients at each dose level receiving 2 million, 5 million, 10 million or 20 million cells). Patients will be admitted to hospital the day before surgery and prepared for CTX cell implantation to take place. Patients will be discharged two days after surgery.
One patient will be treated at a time. An independent Data Safety Monitoring Board (DSMB) will make the decision to continue dosing at each dose level following satisfactory review of the 28 day safety data for the first patient at that dose level; and to increase the dose to the next level following satisfactory review of the 3 month safety data for all three patients in the previous dose group.
Post treatment follow-up of patients: There will be 6 scheduled visits to clinic for monitoring and neurofunctional testing and 5 scheduled telephone contacts to monitor adverse events (AEs) and concomitant medications over the 2 year follow-up period.
End-points: The primary end-point of the trial is safety, measured by numbers of relevant Serious Adverse Events, health screening, neurological assessment and scanning abnormalities. The secondary aim is to evaluate various MRI and other test measures for their potential as efficacy markers for subsequent trials.
Post trial follow up: All trial patients will be flagged by the National Health Service Central Register (NHSCR) Scotland for life-long follow-up. In addition, all patients will be invited to take part in an 8-year follow up trial requiring an annual review by a suitable physician.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01151124
|Division of Clinical Neurosciences, Glasgow Southern General Hospital|
|Glasgow, United Kingdom, G51 4TF|